185 related articles for article (PubMed ID: 25401698)
1. Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6.
Melbø-Jørgensen C; Ness N; Andersen S; Valkov A; Dønnem T; Al-Saad S; Kiselev Y; Berg T; Nordby Y; Bremnes RM; Busund LT; Richardsen E
PLoS One; 2014; 9(11):e113039. PubMed ID: 25401698
[TBL] [Abstract][Full Text] [Related]
2. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
[TBL] [Abstract][Full Text] [Related]
3. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
[TBL] [Abstract][Full Text] [Related]
4. Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells.
Laursen EB; Fredsøe J; Schmidt L; Strand SH; Kristensen H; Rasmussen AKI; Daugaard TF; Mouritzen P; Høyer S; Kristensen G; Stroomberg HV; Brasso K; Røder MA; Borre M; Sørensen KD
Am J Pathol; 2019 Dec; 189(12):2377-2388. PubMed ID: 31539518
[TBL] [Abstract][Full Text] [Related]
5. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer.
Kumar B; Rosenberg AZ; Choi SM; Fox-Talbot K; De Marzo AM; Nonn L; Brennen WN; Marchionni L; Halushka MK; Lupold SE
Sci Rep; 2018 May; 8(1):7189. PubMed ID: 29739972
[TBL] [Abstract][Full Text] [Related]
6. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
7. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer.
Richardsen E; Andersen S; Melbø-Jørgensen C; Rakaee M; Ness N; Al-Saad S; Nordby Y; Pedersen MI; Dønnem T; Bremnes RM; Busund LT
Sci Rep; 2019 Jan; 9(1):386. PubMed ID: 30674952
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
10. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
Prensner JR; Zhao S; Erho N; Schipper M; Iyer MK; Dhanasekaran SM; Magi-Galluzzi C; Mehra R; Sahu A; Siddiqui J; Davicioni E; Den RB; Dicker AP; Karnes RJ; Wei JT; Klein EA; Jenkins RB; Chinnaiyan AM; Feng FY
Lancet Oncol; 2014 Dec; 15(13):1469-1480. PubMed ID: 25456366
[TBL] [Abstract][Full Text] [Related]
11. Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy.
Long Q; Johnson BA; Osunkoya AO; Lai YH; Zhou W; Abramovitz M; Xia M; Bouzyk MB; Nam RK; Sugar L; Stanimirovic A; Williams DJ; Leyland-Jones BR; Seth AK; Petros JA; Moreno CS
Am J Pathol; 2011 Jul; 179(1):46-54. PubMed ID: 21703393
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
13. Circulating microRNAs in plasma before and after radical prostatectomy.
McDonald AC; Raman JD; Shen J; Liao J; Pandya B; Vira MA
Urol Oncol; 2019 Nov; 37(11):814.e1-814.e7. PubMed ID: 31421994
[TBL] [Abstract][Full Text] [Related]
14. Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.
Zheng Q; Peskoe SB; Ribas J; Rafiqi F; Kudrolli T; Meeker AK; De Marzo AM; Platz EA; Lupold SE
Prostate; 2014 Dec; 74(16):1655-62. PubMed ID: 25252191
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.
Schaefer A; Jung M; Mollenkopf HJ; Wagner I; Stephan C; Jentzmik F; Miller K; Lein M; Kristiansen G; Jung K
Int J Cancer; 2010 Mar; 126(5):1166-76. PubMed ID: 19676045
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.
Haldrup C; Mundbjerg K; Vestergaard EM; Lamy P; Wild P; Schulz WA; Arsov C; Visakorpi T; Borre M; Høyer S; Orntoft TF; Sørensen KD
J Clin Oncol; 2013 Sep; 31(26):3250-8. PubMed ID: 23918943
[TBL] [Abstract][Full Text] [Related]
17. A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine.
Fredsøe J; Rasmussen AKI; Mouritzen P; Borre M; Ørntoft T; Sørensen KD
Int J Cancer; 2019 Nov; 145(9):2558-2567. PubMed ID: 30903800
[TBL] [Abstract][Full Text] [Related]
18. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.
Avgeris M; Stravodimos K; Fragoulis EG; Scorilas A
Br J Cancer; 2013 Jun; 108(12):2573-81. PubMed ID: 23703249
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast miR-210 overexpression is independently associated with clinical failure in Prostate Cancer - a multicenter (in situ hybridization) study.
Andersen S; Richardsen E; Moi L; Donnem T; Nordby Y; Ness N; Holman ME; Bremnes RM; Busund LT
Sci Rep; 2016 Nov; 6():36573. PubMed ID: 27824162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
